Incannex Healthcare Inc. reactivated its share repurchase program, with buyback activity occurring over the past two trading days. The Board's decision reflects its view that the company's current market valuation does not accurately reflect its strong balance sheet, clinical progress, and future potential.
Key takeaways
Incannex reactivated its previously approved share repurchase program, with the program having been active over the past two trading days.
The company has approximately $75 million in cash on hand and no debt.
As of December 31, 2025, approximately $18.5 million remained available for repurchases under the share repurchase program.
The company's lead clinical programs include IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder.
The buyback program does not obligate the company to acquire any specific number of shares and may be modified, suspended, or discontinued at any time.